HC Wainwright Reaffirms Neutral Rating for Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ:ALDX)‘s stock had its “neutral” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. They currently have a $2.00 target price on the biotechnology company’s stock, down from their previous target price of $10.00. HC Wainwright’s price objective would suggest a potential upside of 9.29% from the company’s current price.

Separately, BTIG Research reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.50.

Aldeyra Therapeutics Stock Up 28.9%

Aldeyra Therapeutics stock opened at $1.83 on Wednesday. The company has a fifty day simple moving average of $4.82 and a 200-day simple moving average of $5.03. The firm has a market capitalization of $110.13 million, a price-to-earnings ratio of -3.21 and a beta of 0.97. Aldeyra Therapeutics has a 52-week low of $1.07 and a 52-week high of $6.87.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. On average, research analysts anticipate that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ALDX. Caption Management LLC increased its stake in Aldeyra Therapeutics by 110.6% during the 2nd quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock worth $49,000 after buying an additional 132,358 shares during the period. Inspirion Wealth Advisors LLC acquired a new stake in Aldeyra Therapeutics in the 4th quarter valued at about $52,000. Global Retirement Partners LLC purchased a new position in shares of Aldeyra Therapeutics in the 4th quarter valued at about $52,000. BNP Paribas Financial Markets boosted its stake in shares of Aldeyra Therapeutics by 36.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 2,859 shares during the period. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of Aldeyra Therapeutics during the third quarter worth about $55,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Key Stories Impacting Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Insider purchase — Aldeyra Director Michael Alfieri reported buying 5,000 shares at $1.42, boosting his stake 200%. Insider buys can be read as a confidence signal and likely helped lift the stock intraday. SEC Filing: Insider Purchase
• Neutral Sentiment: Data on short interest is reporting zeros/NaN for March (likely a reporting anomaly); days‑to‑cover figures show 0.0 days based on average volume, so short‑interest data is currently uninformative. (No linked source provided in the filing summary.)
• Neutral Sentiment: Analyst stance — HC Wainwright reaffirmed a “neutral” rating but cut the price target to $2.00 (from $10.00), reflecting lower expectations; this is a mixed signal that offers limited upside per the new PT. Benzinga Note
• Negative Sentiment: FDA rejection (CRL) for reproxalap — The FDA issued a third CRL citing insufficient efficacy for the dry‑eye NDA. That regulatory setback is the core reason for the recent ~70% collapse in ALDX shares and remains the primary negative catalyst. Zacks: FDA Issues Third CRL
• Negative Sentiment: Securities‑law actions and investigations — Multiple firms (Levi & Korsinsky, Block & Leviton and others) have launched inquiries and investor alerts alleging misleading statements about reproxalap’s prospects; class actions and investigations increase legal risk and could pressure the stock further. PR Newswire: Investor Alert Newsfile: Block & Leviton
• Negative Sentiment: Options activity — Reports show high volume of put option buying, indicating traders are betting on further downside and adding downward pressure to the share price. AmericanBankingNews: Put Option Activity
• Negative Sentiment: Market reaction commentary — Several outlets note the stock slumped ~67–71% over recent sessions following the CRL; that sharp de‑risking by investors is an ongoing headwind despite today’s bounce. Benzinga: Market Coverage

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.